암 치료제 시장

The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.

The targeted therapy market for oncology pharmaceuticals is estimated to increase from $80.4 billion in 2023 to reach $176.6 billion by 2029, at a CAGR of 14.1% from 2024 through 2029.

The immunotherapy market for oncology pharmaceuticals is estimated to increase from $75.4 billion in 2023 to reach $152.5 billion by 2029, at a CAGR of 12.6% from 2024 through 2029.

Report Scope

This report seeks to deliver an in-depth analysis of the worldwide oncology pharmaceuticals (cancer medications) market. It includes a thorough overview of various types of oncology drugs, such as targeted therapy, immunotherapy, chemotherapy, and hormone therapy, and an examination of current and historical market revenues. The oncology pharmaceuticals market is further categorized by indication, including lung cancer, multiple myeloma, breast cancer, non-Hodgkin's lymphoma, prostate cancer, colorectal cancer, and other types of cancer. Additionally, the report presents the market revenue for each geographic region, including North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

In order to provide an in-depth understanding of the market, this report also includes profiles of market participants, the competitive landscape, key competitors, and respective market share/ranking. This report includes an oncology pharmaceuticals pipeline analysis, patent analysis, and a detailed discussion of key marketed products. This report outlines the driving and restraining factors of the oncology pharmaceuticals market.

By geography, the market in this report is segmented into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

Report Includes

• 70 data tables and 50 additional tables
• Analysis of the global market for oncology pharmaceuticals (cancer drugs)
• Analyses of global market trends, with market revenue data from 2022 to 2023, estimates for 2024, forecast for 2025, and projected CAGRs through 2029
• An assessment of the different oncology pharmaceutical types (targeted therapy, immunotherapy, chemotherapy and hormone therapy) and their current and historical market revenues
• Estimate of the current market size and revenue prospects, along with a market share analysis by drug type, disease indication (application type), and region
• Facts and figures pertaining to the market dynamics, technological advances, regulations, and the macroeconomic factors that influence the industry
• A Porter's Five Forces model, and global supply chain and PESTLE analyses
• An analysis of the key products on the market and promising new pipeline molecules or drugs under development
• A look at the recent patent grants
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
• Analysis of the industry structure, including companies' market shares, strategic alliances, M&A activity and a venture funding outlook
• Company profiles of major players within the industry, including Bristol-Myers Squibb Co., Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Supply Chain Analysis
• Research and Development
• Manufacturing
• Packaging
• Wholesale Distributors and Repackagers
• Pharmacies
• Dispensed to Consumers
• Addressing Challenges in the Pharmaceutical Supply Chain
• Costs
• Regulations
• Safety and Security
• Porter's Five Forces Analysis in the Oncology Market
• Threat of New Entrants
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of Substitute Products or Services
• Industry Rivalry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Increasing Incidence of Cancer Disease
• Robust Approval of Oncology Drugs
• Technological Advances in Cancer Treatments
• Market Challenges
• Loss of Exclusivity and Genericization
• Lack of Oncology Professionals

Chapter 4 Emerging Trends and Pipeline Analysis

• Emerging Technologies
• Personalized Cancer Vaccines
• CAR T-Cell Therapy
• Tablet to Cut Breast Cancer Risk
• Nanoparticles
• Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
• New Developments
• Biosimilar Approvals
• Pipeline Analysis
• Clinical Trial Analysis
• Patent Analysis

Chapter 5 Market Segmentation Analysis

• Segmentation Breakdown
• Global Oncology Pharmaceuticals Market by Drug Type
• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Hormone Therapy
• Global Oncology Pharmaceuticals Market by Cancer Type
• Lung Cancer
• Breast Cancer
• Leukemia
• Melanoma
• Multiple Myeloma
• Prostate Cancer
• Non-Hodgkin's Lymphoma
• Colorectal Cancer
• Other Cancers
• Geographic Breakdown
• Global Oncology Pharmaceuticals Market by Region
• North America
• Europe
• Asia-Pacific
• Rest of World

Chapter 6 Competitive Intelligence

• Overview
• Blockbuster Oncology Pharmaceutical Brands
• Global Market Shares of Leading Companies

Chapter 7 Sustainability in the Oncology Pharmaceuticals Market: ESG Perspective

• Role of ESG in the Pharma Industry
• Environmental
• Social
• Governance
• ESG Risk Ratings
• Conclusion

Chapter 8 Appendix

• Methodology
• Sources
• Acronyms
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.